Skip to main content
SpringerLink
Log in

Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin

  • Living reference work entry
  • First Online:
Critical Care Toxicology

  • 1586 Accesses

Abstract

Microtubules are present in all eukaryotic cells. They are responsible for movement of vesicles within cells, motion of cilia and flagella, and chromosome separation in mitosis. In neurons, microtubules serve as tracks for protein particles and organelles that move up and down the axon. They also can direct proteins for repair of cellular injury. Antitubulin agents, including colchicine, vincristine, vinblastine, and podophyllin, inhibit the construction of microtubules, which accounts for the therapeutic and the toxic actions of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Hood RL. Colchicine poisoning. J Emerg Med. 1994;12:171–7.

    Article  CAS  PubMed  Google Scholar 

  2. Borron S, Scherrmann J, Baud F. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Human Vet Toxicol. 1996;15:885–90.

    Article  CAS  Google Scholar 

  3. Milne ST, Meek PD. Fatal colchicine overdose: report of a case and review of the literature. Am J Emerg Med. 1998;16:603–8.

    Article  CAS  PubMed  Google Scholar 

  4. Nagesh KR, Menezes RG, Rastogi P, Naik NR, Rasquinha JM, Senthilkumaran S, et al. Suicidal plant poisoning with Colchicum autumnale. J Forensic Leg Med. 2011;18:285–7.

    Article  CAS  PubMed  Google Scholar 

  5. Sundov Z, Nincevic Z, Definis-Gojanovic M, Glavina-Durdov M, Jukic I, Hulina N, et al. Fatal colchicine poisoning by accidental ingestion of meadow saffron-case report. Forensic Sci Int. 2005;149:253–6.

    Article  PubMed  Google Scholar 

  6. Mendis S. Colchicine cardiotoxicity following ingestion of Gloriosa superba tubers. Postgrad Med J. 1989;65:752–5. Pubmed Central PMCID: PMC2429836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Woodbury D, Fingl E. Analgesic-antipyretics, antiinflammatory agents, and drugs employed in the therapy of gout. In: Goodman L, Gilman A, editors. The pharmacologic basis of therapeutics. 5th ed. New York: Macmillan; 1975. p. 350–5. I.

    Google Scholar 

  8. Stahl N, Weinberger A, Benjamin D, Pinkhas J. Fatal colchicine poisoning in a boy with familial Mediterranean fever. Am J Med Sci. 1979;278:77–81.

    Article  CAS  PubMed  Google Scholar 

  9. Kaplan H. Sarcoid arthritis with a response to colchicine. N Engl J Med. 1960;263:778–81.

    Article  CAS  PubMed  Google Scholar 

  10. Torres M, Furst D. Treatment of Generalized Systemic Sclerosis. Rheum Dis Clin North Am. 1990;16:217–41.

    CAS  PubMed  Google Scholar 

  11. Cohen A, Rubinow A, Anderson J. Colchicine treated cases from 1976 to 1983 compared with cases seen in previous years. Am J Med. 1987;82:1182–90.

    Article  CAS  PubMed  Google Scholar 

  12. Anonymous. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. 1990;335:1078–80.

    Google Scholar 

  13. Sander H, Randal H. Use of colchicine in Behcet’s syndrome. Cutis. 1986;37:344–8.

    CAS  PubMed  Google Scholar 

  14. Seidman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol. 1987;14:777–9.

    Google Scholar 

  15. Medsger Jr TA. Treatment of systemic sclerosis. Ann Rheum Dis. 1991;50:877–86.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Naidus R, Rodvein R, Meikle H. Colchicine toxicity- a multisystem disease. Arch Intern Med. 1977;137:394–6.

    Article  CAS  PubMed  Google Scholar 

  17. Russell FE, Gertsch WJ. For those who treat spider or suspected spider bites [letter]. Toxicon. 1983;21:337–9.

    Article  CAS  PubMed  Google Scholar 

  18. Keshenobich D, Varga F, Garica-Tsao G. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med. 1988;318:1709–13.

    Article  Google Scholar 

  19. Kaplan M, Alling D, Zimmerman HJ. A prospective trial for colchicine for primary biliary cirrhosis of the liver. N Engl J Med. 1986;315:1448–54.

    Article  CAS  PubMed  Google Scholar 

  20. von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis) [see comments]. J Am Acad Dermatol. 1994;31:535–56. quiz 57–60.

    Article  PubMed  Google Scholar 

  21. Schnebel BE, Simmons JW. The use of oral colchicine for low-back pain. A double-blind study. Spine. 1988;13:354–7.

    Article  CAS  PubMed  Google Scholar 

  22. Simmons JW, Harris WP, Koulisis CW, Kimmich SJ. Intravenous colchicine for low-back pain: a double-blind study. Spine. 1990;15:716–7.

    Article  CAS  PubMed  Google Scholar 

  23. Chyka PA, Seger D, Krenzelok EP, Vale JA, American Academy of Clinical T, European Association of Poisons C, et al. Position paper: single-dose activated charcoal. Clin Toxicol. 2005;43:61–87.

    Article  CAS  Google Scholar 

  24. Centers for Disease C, Prevention. Deaths from intravenous colchicine resulting from a compounding pharmacy error – Oregon and Washington, 2007. MMWR – Morb Mortal Wkly Rep. 2007;56:1050–2.

    Google Scholar 

  25. Sussman JS, Brozena SC, Skop N, Korecka M, Shaw LM. Accidental intravenous colchicine poisoning. Ther Drug Monit. 2004;26:688–92.

    Article  CAS  PubMed  Google Scholar 

  26. Wallace S, Singer J. Review: systemic toxicity associated with the intravenous administration of colchicine-Guidelines for use. J Rheumatol. 1988;15:495–9.

    CAS  PubMed  Google Scholar 

  27. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48:407–14.

    Article  CAS  Google Scholar 

  28. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48–59.

    Article  CAS  PubMed  Google Scholar 

  29. Folpini A, Furfori P. Colchicine toxicity – clinical features and treatment. Massive overdose case report. J Toxicol – Clin Toxicol. 1995;33:71–7.

    Article  CAS  PubMed  Google Scholar 

  30. Wallace SL, Omokoku B, Ertel NH. Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am J Med. 1970;48:443–8.

    Article  CAS  PubMed  Google Scholar 

  31. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–37.

    Article  CAS  PubMed  Google Scholar 

  32. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother. 2005;39:1368–9.

    Article  PubMed  Google Scholar 

  33. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30:799–802.

    Article  PubMed  Google Scholar 

  34. Carral J, Milne V, Underberg A. Rhabdomyolysis in a patient taking colchicine and rosuvastatin. J Clin Lipidol. 2014;8:352–3.

    Article  Google Scholar 

  35. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. JCR: J Clin Rheumatol. 2007;13:266–8.

    PubMed  Google Scholar 

  36. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett R, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheumat. 2010;62:1060–8.

    Article  CAS  PubMed  Google Scholar 

  37. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheumat. 2009;38:411–9.

    Article  CAS  Google Scholar 

  38. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279–304.

    Article  CAS  PubMed  Google Scholar 

  39. Lodish H, Berk A, Zipursky SL, et al. Microtubules and cellular movement. In: Berk A, Zipursky SL, editors. Molecular cell biology. 4th ed. New York: Freeman; 1999. p. 795–897.

    Google Scholar 

  40. Jordan A, Hadfield J, Lawrence N, McGown A. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18:259–96.

    Article  CAS  PubMed  Google Scholar 

  41. Panda D, Jordan M, Chu K, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem. 1996;271:29807–12.

    Article  CAS  PubMed  Google Scholar 

  42. Chang Y. Mechanism of action of colchicine III Antiinflammatory effects of colchicine compared with phenylbutazone and indomethacin. Arthritis Rheum. 1975;18:493–6.

    Article  CAS  PubMed  Google Scholar 

  43. Spilberg I. Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest. 1979;64:775–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Baum J, Meyerowitz S. Colchicine: Its use as a suicidal drug by females. J Rheumatol. 1980;7:124–7.

    CAS  PubMed  Google Scholar 

  45. Wells S, Anderson D. Colchicine toxicity: a case report. Vet Hum Toxicol. 1989;31:313–6.

    CAS  PubMed  Google Scholar 

  46. Murray SS, Kramlinger KG, McMichan JC, Mohr DN. Acute toxicity after excessive ingestion of colchicine. Mayo Clin Proc. 1983;58:528–32.

    CAS  PubMed  Google Scholar 

  47. Ferguson F, Colchicine I. General pharmacology. J Pharmacol Exp Ther. 1952;106:261–70.

    CAS  PubMed  Google Scholar 

  48. Hill R, Spragg R, Wedel M. Adult respiratory distress syndrome associated with colchicine intoxication. Ann Intern Med. 1975;83:523.

    Article  CAS  PubMed  Google Scholar 

  49. Sauder P, Kopferschmitt J, Jaeger A, Mantz JM. Haemodynamic studies in eight cases of acute colchicine poisoning. Hum Toxicol. 1983;2:169–73.

    Article  CAS  PubMed  Google Scholar 

  50. Mullins M, Carrico E, Horowitz B. Fatal cardiovascular collapse following acute colchicine ingestion. J Toxicol Clin Toxicol. 2000;38:51–4.

    Article  CAS  PubMed  Google Scholar 

  51. Heath D, Palmer J, Aurbach G. The hypocalcemic action of colchicine. Endocrinology. 1972;90:1589–93.

    Article  CAS  PubMed  Google Scholar 

  52. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316:1562–8.

    Article  CAS  PubMed  Google Scholar 

  53. Neuss M. McCallum Rea. Long-term colchicine administration leading to colchicine toxicity and death. Arthritis Rheum. 1986;29:448–9.

    Article  CAS  PubMed  Google Scholar 

  54. Ellwood MG, Robb GH. Self-poisoning with colchicine. Postgrad Med J. 1971;47:129–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gooneratne BW. Massive generalized alopecia after poisoning by Gloriosa superba. Br Med J. 1966;5494:1023–4.

    Article  Google Scholar 

  56. Stanley MW, Taurog JD, Snover DC. Fatal colchicine toxicity: report of a case. Clin Exp Rheumatol. 1984;2:167–71.

    CAS  PubMed  Google Scholar 

  57. Critchley J, Critchley L, Yeung E. Granuloctye-colony stimulating factor in the treatment of colchicine poisoning. Hum Exp Toxicol. 1997;16:229–32.

    Article  CAS  PubMed  Google Scholar 

  58. Harris R, Marx G. Colchicine-induced bone marrow suppression: treatment with granulocyte colony stimulating factor. J Emerg Med. 2000;18:435–40.

    Article  CAS  PubMed  Google Scholar 

  59. Wolff J, Capraro H. Colchicine binding to antibodies. J Biol Chem. 1980;255:7144–8.

    CAS  PubMed  Google Scholar 

  60. Terrien N, Urtizberea M, Schermann J. Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicol Appl Pharmacol. 1990;104:504–10.

    Article  CAS  PubMed  Google Scholar 

  61. Baud F. Sabourand Aea. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med. 1995;332:642–5.

    Article  CAS  PubMed  Google Scholar 

  62. Ozdemir R, Bayrakci B, Teksam O. Fatal poisoning in children: acute colchicine intoxication and new treatment approaches. Clin Toxicol. 2011;49:739–43.

    Article  CAS  Google Scholar 

  63. Tutar HE, Imamoglu A, Atalay S. Recurrent pericarditis in familial Mediterranean fever [letter; comment]. Acta Paediatr. 1999;88:1045–6.

    Article  CAS  PubMed  Google Scholar 

  64. Sadjadi SJ, Moshir M. Treatment of acne vulgaris with colchicine [letter] [see comments]. Acta Derm Venereol. 1998;78:388.

    Article  CAS  PubMed  Google Scholar 

  65. Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol. 1999;31:619–31.

    Article  CAS  PubMed  Google Scholar 

  66. Yazigi A, Abou-Charaf LC. Colchicine for recurrent pericarditis in children [see comments]. Acta Paediatr. 1998;87:603–4.

    Article  CAS  PubMed  Google Scholar 

  67. Bicer S, Soysal DD, Ctak A, Ucsel R, Karabocuoglu M, Uzel N. Acute colchicine intoxication in a child: a case report. Pediatr Emerg Care. 2007;23:314–7.

    Article  PubMed  Google Scholar 

  68. Goldbart A, Press J, Sofer S, Kapelushnik J. Near fatal acute colchicine intoxication in a child. A case report. Eur J Pediatr. 2000;159:895–7.

    Article  CAS  PubMed  Google Scholar 

  69. Kilic SC, Alaygut D, Unal E, Koc E, Patiroglu T. Acute colchicine intoxication complicated with extramedullary hematopoiesis due to filgrastim in a child. J Pediatr Hematol Oncol. 2014;36:e460–2.

    Article  PubMed  Google Scholar 

  70. Carrington CV. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. J Oncol Pharm Pract. 2006;12:113–8.

    Article  PubMed  Google Scholar 

  71. Crom W, DeGraff S, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125:642.

    Article  CAS  PubMed  Google Scholar 

  72. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy. 1998;18:1304–7.

    CAS  PubMed  Google Scholar 

  73. Sahenk Z, Brady S, Mendell J. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80–4.

    Article  CAS  PubMed  Google Scholar 

  74. Schlaepfer W. Vincristine-induced axonal alteration in rat peripheral nerve. J Neuropathol Exp Neurol. 1971;30:488–505.

    Article  CAS  PubMed  Google Scholar 

  75. Chae L, Moon H, Kim S. Overdose of vincristine: experience with a patient. J Korean Med Sci. 1998;13:334–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Mcleod J, Peny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry. 1969;32:297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Suzuki D, Inamoto J, Ohshima J, Cho Y, Saitoh S, Kaneda M, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol. 2012;34:239–41.

    Article  PubMed  CAS  Google Scholar 

  78. Mahajan S. Acute acoustic nerve palsy associated with vincristine therapy. Cancer. 1981;47:2404.

    Article  CAS  PubMed  Google Scholar 

  79. Dallera F, Gamoletti R, Costa P. Unilateral seizures following vincristine intravenous injection. Tumori. 1984;70:243–4.

    CAS  PubMed  Google Scholar 

  80. Hurwitz RL, Mahoney Jr DH, Armstrong DL, Browder TM. Reversible encephalopathy and seizures as a result of conventional vincristine administration [see comments]. Med Pediatr Oncol. 1988;16:216–9.

    Article  CAS  PubMed  Google Scholar 

  81. Casteels-Van Daele M, Beirinckx J, Baines P. Overdosage with vincristine. J Pediatr. 1977;90:1042–3.

    Article  Google Scholar 

  82. Johnson FL, Bernstein ID, Hartmann JR, Chard Jr RL. Seizures associated with vincristine sulfate therapy. J Pediatr. 1973;82:699–702.

    Article  CAS  PubMed  Google Scholar 

  83. Kaufman I, Dung F, Koenig H, Giammona S. Overdosage with vincristine. J Pediatr. 1976;89:671–4.

    Article  CAS  PubMed  Google Scholar 

  84. Trinkle R, Wu JK. Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol. 1996;26:344–51.

    Article  CAS  PubMed  Google Scholar 

  85. Suskind R, Brusilow S, Zehr J. Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level). J Pediatr. 1972;81:90–2.

    Article  CAS  PubMed  Google Scholar 

  86. Meggs W, Hoffman R. Fatality resulting from intraventricular vincristine administration. Clin Toxicol. 1998;36:243–6.

    CAS  Google Scholar 

  87. Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst. 1985;74:113–20.

    CAS  PubMed  Google Scholar 

  88. Conter V, Rabbone ML, Jankovic M, Fraschini D, Corbetta A, Pacheco C, et al. Overdose of vinblastine in a child with Langerhans’ cell histiocytosis: toxicity and salvage therapy [see comments]. Pediatr Hematol Oncol. 1991;8:165–9.

    Article  CAS  PubMed  Google Scholar 

  89. Fiorentino MV, Salvagno L, Chiarion Sileni V, Paccagnella A, Ferrazzi E, Zagonel V, et al. Vindesine overdose [letter]. Cancer Treat Rep. 1982;66:1247–8.

    CAS  PubMed  Google Scholar 

  90. Gutowski MC, Fix DV, Corvalan JR, Johnson DA. Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody. Cancer Invest. 1995;13:370–4.

    Article  CAS  PubMed  Google Scholar 

  91. Lotz JP, Chapiro J, Voinea A, Cornu P, Pene F, Bazelly B, et al. Overdosage of vinorelbine in a woman with metastatic non-small-cell lung carcinoma [letter]. Ann Oncol. 1997;8:714–5.

    Article  CAS  PubMed  Google Scholar 

  92. Kouroukis C, Hings I. Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer. Chest. 1997;112:846–8.

    Article  CAS  PubMed  Google Scholar 

  93. Lejonc J, Vernant J, MacQuin I, et al. Myocardial infarction following vinblastine treatment. Lancet. 1980;2:692.

    Article  CAS  PubMed  Google Scholar 

  94. Mandel E, Lewinski U, Djaldetti M. Vincrisine induced myocardial infarction. Cancer. 1975;36:1979–82.

    Article  CAS  PubMed  Google Scholar 

  95. Subar M, Muggia F. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep. 1986;70:690–1.

    CAS  PubMed  Google Scholar 

  96. Yancey R, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep. 1982;66:587–9.

    CAS  PubMed  Google Scholar 

  97. McLendon B, Bron A. Corneal toxicity from vinblastine solution. Br J Ophthalmol. 1978;62:97–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Raderer M, Kornek G, Scheithauer W. Re: Vinorelbine-induced pancreatitis: a case report [letter; comment]. J Natl Cancer Inst. 1998;90:329.

    Article  CAS  PubMed  Google Scholar 

  99. Tester W, Forbes W, Leighton J. Vinorelbine-induced pancreatitis: a case report [letter] [see comments]. J Natl Cancer Inst. 1997;89:1631.

    Article  CAS  PubMed  Google Scholar 

  100. Garrett CA, Simpson Jr TA. Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Ann Pharmacother. 1998;32:1306–9.

    Article  CAS  PubMed  Google Scholar 

  101. Winter S, Arbus G. Syndrome of inappropriate secretion of antidiuretic hormone secondary to vinblastine overdose. CMA J. 1977;117:1134.

    CAS  Google Scholar 

  102. Lobert S, Ingram J, Correia J. Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly. Cancer Res. 1999;59:4816–22.

    CAS  PubMed  Google Scholar 

  103. Pierga J, Beuzeboc P, Dorval T, Palangie T, Pouillart P. Favourable outcome after plasmapheresis for vincristine overdose. Lancet. 1992;340:185.

    Article  CAS  PubMed  Google Scholar 

  104. Gale RP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol. 1985;13:3–7.

    CAS  PubMed  Google Scholar 

  105. Thomas W, Bailony M, Lightsey A, Lew S, Barnet W. Folinic acid rescue in vincristine overdosage in mice. Am J Pediatr Hematol Oncol. 1986;8:266–8.

    Article  CAS  PubMed  Google Scholar 

  106. Jackson D, Wells H, Atkins J, Zekan P, White D, Richards F, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med. 1988;84:1016–22.

    Article  CAS  PubMed  Google Scholar 

  107. Gilbar PJ, Dooley MJ. Review of case reports of inadvertent intrathecal administration of vincristine: recommendations to reduce occurrence. Asia Pac J Clin Oncol. 2007;3:59–65.

    Article  Google Scholar 

  108. Kawakami K, Kumamoto T, Tonooka S, Abe A, Hayasaka K, Okamoto Y, et al. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30:519–21.

    Article  PubMed  Google Scholar 

  109. Manelis J, Freundlich E, Ezekiel E, Doron J. Accidental intrathecal vincristine administration. J Neurol. 1982;228:209–13.

    Article  CAS  PubMed  Google Scholar 

  110. Williams ME, Walker AN, Bracikowski JP, Garner L, Wilson KD, Carpenter JT. Ascending myeloencephalopathy due to intrathecal vincristine sulfate: a fatal chemotherapeutic error. Cancer. 1983;51:2041–7.

    Article  CAS  PubMed  Google Scholar 

  111. Gaidys W, Dickerman J, Walters C, Young P. Intrathecal vincristine: report of a fatal case despite CNS washout. Cancer. 1983;52:799–801.

    Article  CAS  PubMed  Google Scholar 

  112. Lau G. Accidental intraventricular vincristine administration: an avoidable iatrogenic death. Med Sci Law. 1996;36:263–5.

    CAS  PubMed  Google Scholar 

  113. al Fawaz IM. Fatal myeloencephalopathy due to intrathecal vincristine administration. Ann Trop Paediatr. 1992;12:339–42.

    PubMed  Google Scholar 

  114. Zaragoza MR, Ritchey ML, Walter A. Neurourologic consequences of accidental intrathecal vincristine: a case report. Med Pediatr Oncol. 1995;24:61–2.

    Article  CAS  PubMed  Google Scholar 

  115. Dyke R. Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med. 1989;321:1270–1.

    CAS  PubMed  Google Scholar 

  116. Ferayan A, Russell N, Wohaibi M, Awada A, Scherman B. Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection. Child’s Nerv Syst. 1999;15:87–9.

    Article  Google Scholar 

  117. Available from: http://medicine.iupui.edu/clinpharm/ddis/main-table/.

  118. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol. 1996;37:351–5.

    Article  CAS  PubMed  Google Scholar 

  119. Boula AM, Mantadakis E, Xilouri IM, Christoforidou AV, Foudoulakis AM, Samonis G. Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. Am J Hematol. 2005;79:216–9.

    Article  CAS  PubMed  Google Scholar 

  120. Bisogno G, de Kraker J, Weirich A, Masiero L, Ludwig R, Tournade MF, et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol. 1997;29:245–51.

    Article  CAS  PubMed  Google Scholar 

  121. Ichikawa M, Suzuki D, Inamoto J, Ohshima J, Cho Y, Saitoh S, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol. 2012;34:239–41.

    Article  CAS  PubMed  Google Scholar 

  122. Pascual-Huerta J, Perez-Melero A. Charcot-Marie-Tooth disease and vincristine. J Am Podiatr Med Assoc. 2003;93:229–33.

    Article  PubMed  Google Scholar 

  123. Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B, Pediatric Oncology Group S. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003;25:316–20.

    Article  PubMed  Google Scholar 

  124. Ntaios G, Kaiafa G, Girtovitis F, Saouli Z, Kontoninas Z, Diamantidis MD, et al. Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia. Int J Hematol. 2008;88:441–2.

    Article  PubMed  Google Scholar 

  125. Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol. 2005;27:389–92.

    Article  PubMed  Google Scholar 

  126. Brumen V, Horvat D. Work environment influence on cytostatics-induced genotoxicity in oncologic nurses. Am J Ind Med. 1996;30:67–71.

    Article  CAS  PubMed  Google Scholar 

  127. Cave TA, Norman P, Mellor D. Cytotoxic drug use in treatment of dogs and cats with cancer by UK veterinary practices (2003 to 2004). J Small Anim Pract. 2007;48:371–7.

    Article  CAS  PubMed  Google Scholar 

  128. Hamscher G, Mohring SA, Knobloch A, Eberle N, Nau H, Nolte I, et al. Determination of drug residues in urine of dogs receiving anti-cancer chemotherapy by liquid chromatography-electrospray ionization- tandem mass spectrometry: is there an environmental or occupational risk? J Anal Toxicol. 2010;34:142–8.

    Article  CAS  PubMed  Google Scholar 

  129. Kusnetz E, Condon M. Acute effects from occupational exposure to antineoplastic drugs in a para-professional health care worker. Am J Ind Med. 2003;44:107–9.

    Article  PubMed  Google Scholar 

  130. Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol. 1996;37:351–5.

    Article  PubMed  Google Scholar 

  131. Chui FC. Podophyllotoxin and related compounds. In: Herbert H, Schumburg PSS, editors. Experimental and clinical neurotoxicology. 2nd ed. New York: Oxford University Press; 2000. p. 1008–10.

    Google Scholar 

  132. Stahelin HF, Von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res. 1991;51:5–15.

    CAS  PubMed  Google Scholar 

  133. Vogelzang NJ, Raghavan D, Kennedy BJ. VP-16-213 (Etoposide): The Mandrake Root from Issyk-Kul. Am J Med. 1982;72:136–44.

    Article  CAS  PubMed  Google Scholar 

  134. Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: Vincent TDJHS, editor. Cancer – principle and practice of oncology, vol. 1. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 452–67.

    Google Scholar 

  135. Campbell AN. Accidental poisoning with podophyllum. Lancet. 1980;1:206–7.

    Article  CAS  PubMed  Google Scholar 

  136. Cassidy DE, Drewry J, Fanning JP. Podophyllum toxicity: a report of a fatal case and a review of the literature. J Toxicol – Clin Toxicol. 1982;19:35–44.

    Article  CAS  PubMed  Google Scholar 

  137. Chamberlain MJ, Reynolds AL, Yeoman WB. Medical memoranda. Toxic effect of podophyllum application in pregnancy. Br Med J. 1972;3:391–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Clark ANG, Parsonage MJ. A case of podophyllum poisoning with involvement of the central nervous system. BMJ. 1957;2:1155–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Coruh M, Argun G. Podophyllin poisoning. A case report. Turk J Pediatr. 1965;7:100–3.

    CAS  PubMed  Google Scholar 

  140. McFarland MF, McFarland J. Accidental ingestion of Podophyllum. Clin Toxicol. 1981;18:973–7.

    Article  CAS  PubMed  Google Scholar 

  141. Montaldi DH, Giambrone JP, Courey NG, Taefi P. Podophyllin poisoning associated with the treatment of condylomata acuminatum: a case report. Am J Obstet Gynecol. 1974;119:1130–1.

    CAS  PubMed  Google Scholar 

  142. Rate RG, Leche J, Chervenak C. Podophyllin toxicity. Ann Intern Med. 1979;90:723.

    Article  CAS  PubMed  Google Scholar 

  143. Slater GE, Rumack BH, Peterson RG. Podophyllin poisoning: systemic toxicity following cutaneous application. Obstet Gynecol. 1978;52:94–6.

    CAS  PubMed  Google Scholar 

  144. West WM, Ridgeway NA, Morris AJ, Sides PJ. Fatal Podophyllin ingestion. South Med J. 1982;75:1269–70.

    Article  CAS  PubMed  Google Scholar 

  145. Frasca T, Brett AS, Yoo SD. Mandrake toxicity. A case of mistaken identity. Arch Intern Med. 1997;157:2007–9.

    Article  CAS  PubMed  Google Scholar 

  146. Chang MH, Liao KK, Wu ZA, Liao KK. Reversible myeloneuropathy resulting from podophyllin intoxication: an electrophysiological follow up. J Neurol Neurosurg Psychiatry. 1992;55:235–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Chu CC, Huang CC, Chu NS. Sensory Neuropathy due to Bajiaolian (podophyllotoxin) intoxication. Eur Neurol. 2000;44:121–3.

    Article  CAS  PubMed  Google Scholar 

  148. Dobb GJ, Edis RH. Coma and neuropathy after ingestion of herbal laxative containing podophyllin. Med J Aust. 1984;140:495–6.

    CAS  PubMed  Google Scholar 

  149. Ng TH, Chan YW, Yu YL, Chang CM, Ho HC, Leung SY, et al. Encephalopathy and neuropathy following ingestion of a Chinese herbal broth containing podophyllin. J Neurol Sci. 1991;101:107–13.

    Article  CAS  PubMed  Google Scholar 

  150. Anonymous. Podofilox for genital warts. Med Lett Drugs Ther. 1991;33:117–8.

    Google Scholar 

  151. Bonnez W, Elswick Jr RK, Bailey-Farchione A, Hallahan D, Bell R, Isenberg R, et al. Efficacy and safety of 0.5 % podofilox solution in the treatment and suppression of anogenital warts. Am J Med. 1994;96:420–5.

    Article  CAS  PubMed  Google Scholar 

  152. Gowdey G, Lee RK, Carpenter WM. Treatment of HIV-related hairy leukoplakia with podophyllum resin 25 % solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont. 1995;79:64/7.

    Google Scholar 

  153. Anonymous. Podophyllotoxin derivatives. In: Kastrup E, editor. Drug facts and comparisons. St Louis: Wolters & Kluwer; 2000. p. 1879–81.

    Google Scholar 

  154. Arnold AM, Whitehouse JM. Etoposide: a new anti-cancer agent. Lancet. 1981;2:912–5.

    Article  CAS  PubMed  Google Scholar 

  155. Donehower R, Rowinsky E. DNA Topoisomerase II Inhibitors. In: Perry MC, editor. Chemotherapy source book. 2nd ed. Baltimore: William & Wilkins; 1996. p. 434–45.

    Google Scholar 

  156. Anonymous. Condylox Gel 0.5 %. In: Murray L, editor. Physician’s desk reference. 55th ed. Montvale: Medical Economics; 2001. p. 2248–9.

    Google Scholar 

  157. Stoehr GP, Peterson AL, Taylor WJ. Systemic complications of local podophyllin therapy. Ann Intern Med. 1978;89:362–3.

    Article  CAS  PubMed  Google Scholar 

  158. Anonymous. Cavinton, injection, tablet. Geographia Medica. 1984;14:361–3.

    Google Scholar 

  159. Hoffe PA. Cell cycle, mitosis, and meiosis. Medical molecular genetics. Madison: Fence Creek Publishing; 1998. p. 92–102.

    Google Scholar 

  160. Loike JD, Horowitz SB. Effects of Podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry. 1976;15:5434–43.

    Google Scholar 

  161. Filley CM, Graff-Radford NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology. 1982;32:308–11.

    Article  CAS  PubMed  Google Scholar 

  162. Grieder A, Maurer R, Stahelin H. Effect of an epipodophyllotoxin derivative (VP 16–213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Res. 1974;34:1788–93.

    CAS  PubMed  Google Scholar 

  163. Krishan A. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol. 1975;66:521–30.

    Article  CAS  PubMed  Google Scholar 

  164. Laprevote-Heully MC, Lambert H, Larcan A. Letter: syncope due to arrhythmia. Role of vincamine apropos of 3 observations. Nouv Presse Med. 1974;3:825.

    CAS  PubMed  Google Scholar 

  165. Grieder A, Maurer R, Stahelin H. Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer Res. 1977;37:2998–3005.

    CAS  PubMed  Google Scholar 

  166. Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horowitz SB. Structure activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res. 1978;38:2688–93.

    CAS  PubMed  Google Scholar 

  167. Kalwinsky DK, Look AT, Ducore J, Fridland A. Effects of the epipodophyllotoxin VP 16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res. 1983;43:1592–7.

    CAS  PubMed  Google Scholar 

  168. Long BH, Minocha A. Inhibition of topoisomerase II by VP-16-213 (etoposide), VM-26 (teniposide), and structural congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc Am Assoc Cancer Res. 1983;24:321.

    Google Scholar 

  169. Cao B, Chen H, Gao Y, Niu C, Zhang Y, Li L. CIP-36, a novel topoisomerase II-targeting agent, induces the apoptosis of multidrug-resistant cancer cells in vitro. Int J Mol Med. 2015;35:771–6. Epub 2015/01/17. eng.

    CAS  PubMed  Google Scholar 

  170. Chen H, Wang J, Zhang J, Wang Y, Cao B, Bai S, et al. L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line. Biol Pharm Bull. 2009;32:609–13. Epub 2009/04/02. eng.

    Article  CAS  PubMed  Google Scholar 

  171. Kumar A, Kumar V, Alegria AE, Malhotra SV. Synthetic and application perspectives of azapodophyllotoxins: alternative scaffolds of podophyllotoxin. Curr Med Chem. 2011;18:3853–70. Pubmed Central PMCID: Pmc3278234, Epub 2011/08/10. eng.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Liu YQ, Tian J, Qian K, Zhao XB, Morris-Natschke SL, Yang L, et al. Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents. Med Res Rev. 2015;35:1–62. Pubmed Central PMCID: Pmc4337794, Epub 2014/05/16. eng.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  173. O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med. 1985;312:692–700.

    Article  PubMed  Google Scholar 

  174. Hawkins MM. Secondary leukaemia after epipodophyllotoxins [letter; comment]. Lancet. 1991;338:1408.

    Article  CAS  PubMed  Google Scholar 

  175. Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet. 1993;342:819–20.

    Article  CAS  PubMed  Google Scholar 

  176. Habibi B, Baumelou A, Seradaru M. Acute intravascular haemolysis and renal failure due to teniposide related antibody [letter]. Lancet. 1981;1:1423–4.

    Article  CAS  PubMed  Google Scholar 

  177. McLeod HL, Baker DK, Pui C, Rodman JH. Somnolence, hypotension, and metabolic acidosis following high dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol. 1991;29:150.

    Article  CAS  PubMed  Google Scholar 

  178. Imrie KR, Couture F, Turner CC, Sutcliffe SB, Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant. 1994;13:77–9.

    CAS  PubMed  Google Scholar 

  179. Thant M, Hawley RJ, Smith MT, Cohen MH, Minna JD, Bunn PA, et al. Possible enhancement of vincristine neuropathy by VP-16. Cancer. 1982;49:859–64.

    Article  CAS  PubMed  Google Scholar 

  180. Leff RS, Thompson JM, Daly MB, Johnson DB, Harden EL, Mercier RJ, et al. Acute neurologic dysfunction after high dose etoposide therapy for malignant glioma. Cancer. 1988;62:32–5.

    Article  CAS  PubMed  Google Scholar 

  181. Pawlicki M, Zuchowska-Vogelgesang B, Sliz E. The case of Vepesid overdosage in a patient with Hodgkin’s disease. Cancer Chemother Pharmacol. 1990;25:387.

    Article  CAS  PubMed  Google Scholar 

  182. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33. Epub 2010/06/11. eng.

    Article  CAS  PubMed  Google Scholar 

  183. Dudley WH. Fatal podophyllin poisoning. Med Rec. 1890;37:409.

    Google Scholar 

  184. Gorin F, Kindall D, Seyal M. Dorsal radiculopathy resulting from podophyllin toxicity. Neurology. 1989;39:607–8.

    Article  CAS  PubMed  Google Scholar 

  185. Heath A, Mellstrand T, Ahlmen J. Treatment of podophyllin poisoning with resin hemoperfusion. Hum Toxicol. 1982;1:373–8.

    Article  CAS  PubMed  Google Scholar 

  186. Kumar M, Shanmugham A, Prabha S, Adhisivam B, Narayanan P, Biswal N. Permanent neurological sequelae following accidental podophyllin ingestion. J Child Neurol. 2012;27:209–10. Epub 2011/09/14. eng.

    Article  PubMed  Google Scholar 

  187. Oliveira AS, Calia LC, Kiyomoto BH, Povoa EF, Schmidt B, Gabbai AA. Acute necrotizing myopathy and podophyllin toxicity. Arq Neuropsiquiatr. 1996;54:288–92.

    CAS  PubMed  Google Scholar 

  188. Moher LM, Maurer SA. Podophyllum toxicity: case report and literature review. J Fam Pract. 1979;9:237.

    CAS  PubMed  Google Scholar 

  189. Ward JW, Clifford WS, Monaco AR, Bickerstaff HS. Fatal systemic poisoning following podophyllin treatment of condyloma acuminatum. South Med J. 1954;47:1204–6.

    Article  CAS  PubMed  Google Scholar 

  190. Tomczak RL, Hake DH. Near fatal systemic toxicity from local injection of podophyllin for pedal verrucae treatment. J Foot Surg. 1992;31:36–42.

    CAS  PubMed  Google Scholar 

  191. Freeman MC, Weimer LH, Arnaudo E, Brust JCM. Neuropathic and autonomic effects of intramuscular podophyllin. Ann Neurol. 1997;42:416.

    Article  Google Scholar 

  192. Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine [see comments]. Anesth Analg. 1990;71:191–3.

    Article  CAS  PubMed  Google Scholar 

  193. Chang MH, Lin KP, Wu ZA, Liao KK. Acute ataxic sensory neuropathy resulting from podophyllin intoxication. Muscle Nerve. 1992;15:513–4.

    Article  CAS  PubMed  Google Scholar 

  194. Cabrera Rodriguez J, Munoz GJ. Acute pain due to vinorelbine. Rev Clin Esp. 1998;198:514–6.

    CAS  PubMed  Google Scholar 

  195. O’Mahony S, Keohane C, Jacobs J, O’Riordan D, Whelton M. Neuropathy due to podophyllin intoxication. J Neurol. 1990;237:110–2.

    Article  PubMed  Google Scholar 

  196. Chan YW. Magnetic resonance imaging in toxic encephalopathy due to podophyllin poisoning. Neuroradiology. 1991;33:372–3.

    Article  CAS  PubMed  Google Scholar 

  197. Leslie KO, Shitamoto B. The bone marrow in systemic podophyllin toxicity. Am J Clin Pathol. 1982;77:478–80.

    Article  CAS  PubMed  Google Scholar 

  198. Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, et al. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Clin Cancer Res. 1997;3(9):1519–26.

    CAS  PubMed  Google Scholar 

  199. Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Lombardi F, et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol. 1992;10(12):1955–62.

    CAS  PubMed  Google Scholar 

  200. Jakacki RI, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med Pediatr Oncol. 1997;29(6):553–9.

    Article  CAS  PubMed  Google Scholar 

  201. Maslak PG, Weiss MA, Berman E, Yao TJ, Tyson D, Golde DW, et al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia. 1996;10(1):32–9.

    CAS  PubMed  Google Scholar 

  202. Neill HB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Semin Oncol. 1997;24(4 Suppl 12):S12-130–4.

    Google Scholar 

  203. Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S, Hainsworth J, et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion. 1997;37(9):896–903.

    Article  CAS  PubMed  Google Scholar 

  204. Karol MD, Conner CS, Murphrey KJ. Podophyllum: suspected teratogenicity from topical application. Clin Toxicol. 1980;16:283–6.

    Article  CAS  PubMed  Google Scholar 

  205. Rosenstein G, Rosenstein H, Freeman M, Weston N. Podophyllum-a dangerous laxative. Pediatrics. 1976;57:419–21.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Jerry W. Snow, Louise W. Kao & R. Brent Furbee

Authors
  1. Jerry W. Snow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louise W. Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Brent Furbee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jerry W. Snow .

Editor information

Editors and Affiliations

  1. University of Colorado School of Medicine, Toxicology Associates, Denver, Colorado, USA

    Jeffrey Brent

  2. Office of New Drugs Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA

    Keith Burkhart

  3. Clinical Toxicology, St Thomas' Hospital, London, United Kingdom

    Paul Dargan

  4. University of Colorado School of Medicine, Toxicology Associates, Denver, Colorado, USA

    Benjamin Hatten

  5. Med & Toxicological Intensive Care Unit, Lariboisière Hospital Paris-Diderot University, Paris, France

    Bruno Megarbane

  6. University of Colorado School of Medicine, Toxicology Associates, Denver, Colorado, USA

    Robert Palmer

Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition

  1. I

    Evidence obtained from at least one properly randomized controlled trial.

  2. II-1

    Evidence obtained from well-designed controlled trials without randomization.

  3. II-2

    Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.

  4. II-3

    Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.

  5. III

    Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this entry

Cite this entry

Snow, J., Kao, L., Furbee, R. (2016). Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin. In: Brent, J., Burkhart, K., Dargan, P., Hatten, B., Megarbane, B., Palmer, R. (eds) Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-20790-2_138-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20790-2_138-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-3-319-20790-2

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation